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Simple Summary: Improvement in melanoma patients with metastatic disease is needed to better
assess immunotherapies. Lactate dehydrogenase (LDH) is currently an accepted biomarker for
stage IV, but it has limited utility for stage III melanoma patients. Thus, finding biomarkers for
metastatic melanoma is important not only to identify progressive melanoma tumors, but also to
monitor patients under checkpoint inhibitor immunotherapy (CII). The aim of this pilot study was to
demonstrate the utility of circulating cell-free microRNAs (cfmiRs) as potential blood biomarkers for
stage III and IV melanoma patients compared to LDH. To accomplish this aim, we profiled for cfmiR
the plasma of metastatic melanoma patients before and during CII treatment, and compared them to
normal healthy donors’ samples. The cfmiR profiling was performed using an NGS-based miRNA
assay, which requires no extraction and a small volume input. We found specific cfmiR signatures in
stage III and IV metastatic melanoma patients. As a proof of concept, our results showed that certain
cfmiRs are associated with CII outcomes.
Abstract: Serum lactate dehydrogenase (LDH) is a standard prognostic biomarker for stage IV
melanoma patients. Often, LDH levels do not provide real-time information about the metastatic
melanoma patients’ disease status and treatment response. Therefore, there is a need to find reliable
blood biomarkers for improved monitoring of metastatic melanoma patients who are undergoing
checkpoint inhibitor immunotherapy (CII). The objective in this prospective pilot study was to
discover circulating cell-free microRNA (cfmiR) signatures in the plasma that could assess melanoma
patients’ responses during CII. The cfmiRs were evaluated by the next-generation sequencing (NGS)
HTG EdgeSeq microRNA (miR) Whole Transcriptome Assay (WTA; 2083 miRs) in 158 plasma samples
obtained before and during the course of CII from 47 AJCC stage III/IV melanoma patients’ and
73 normal donors’ plasma samples. Initially, cfmiR profiles for pre- and post-treatment plasma samples
of stage IV non-responder melanoma patients were compared to normal donors’ plasma samples.
Using machine learning, we identified a 9 cfmiR signature that was associated with stage IV melanoma
patients being non-responsive to CII. These cfmiRs were compared in pre- and post-treatment plasma
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samples from stage IV melanoma patients that showed good responses. Circulating miR-4649-3p,
miR-615-3p, and miR-1234-3p demonstrated potential prognostic utility in assessing CII responses.
Compared to LDH levels during CII, circulating miR-615-3p levels were consistently more efficient
in detecting melanoma patients undergoing CII who developed progressive disease. By combining
stage III/IV patients, 92 and 17 differentially expressed cfmiRs were identified in pre-treatment plasma
samples from responder and non-responder patients, respectively. In conclusion, this pilot study
demonstrated cfmiRs that identified treatment responses and could allow for real-time monitoring of
patients receiving CII.
Keywords: serum LDH; blood biomarker; miRNA; circulating microRNA; plasma; immunotherapy;
immune checkpoint inhibitors; metastatic melanoma
1. Introduction
Over the past decade, checkpoint inhibitor immunotherapy (CII) has significantly improved
the outcomes of metastatic melanoma patients [1]. The CII monoclonal antibodies approved to treat
metastatic melanoma patients include ipilimumab (targeting cytotoxic T lymphocyte-associated antigen
4, CTLA-4) [2], nivolumab and pembrolizumab (targeting programmed cell death protein-1, PD-1) [3].
Ipilimumab, nivolumab, and pembrolizumab represent the standard of care and are the most commonly
utilized CII for treating metastatic melanoma patients [4]. One of the advantages of specific CII regimens
is the durable response observed in melanoma patients even after treatment discontinuation, which can
vary depending on the individual or combinatory CII implemented. Unfortunately, the complete
response (CR) rate in melanoma patients is about 12–15% [5,6]. Major limitations for CIIs are primary
and acquired CII resistance. Another limitation is the development of severe immune-related adverse
events (IRAE), which forces the oncologist to discontinue the patient’s treatment [7]. Different tumor
responses, tumor microenvironment changes, and host systemic immune responses play interactive
roles in CII resistance, and IRAE [7,8]. Unfortunately, no key consistent findings and biomarkers have
been found to identify these induced CII events earlier on patients.
Lactate dehydrogenase (LDH) is an enzyme involved in glucose metabolism that is highly
expressed in rapidly growing tumors [9,10]. Due to the high energy demand from the tumor
cells, glycolysis shifts from aerobic to anaerobic in a process called the Warburg effect [9].
Consequently, LDH expression increases in the cytosol of tumor cells, but in general will only
reach the blood stream when the damaged cells release LDH [9]. Several prognostic blood biomarkers
have been proposed for melanoma, but only serum LDH has been accepted as a prognostic
biomarker for stage IV metastatic melanoma by the American Joint Committee on Cancer (AJCC) [11].
Therefore, the prognostic value of LDH has been assessed in metastatic melanoma patients receiving CII.
In a prospective study, LDH and S100B have both been shown to be indicators of disease progression,
although S100B was shown to be a better predictor of the development of distant metastasis [12].
Nevertheless, both failed at identifying high-risk patients with loco-regional metastasis and low tumor
burden [12]. Elevated baseline LDH is an independent prognostic factor for overall survival (OS)
in melanoma patients receiving ipilimumab [13], pembrolizumab, or ipilimumab and nivolumab
combined [14]. Moreover, among different prognostic factors (LDH, tumor size, tumor PD-L1 status,
ECOG performance status, BRAF mutation status, prior BRAF inhibitor targeted therapy, prior line of
therapies, size of metastasis, and albumin levels), only low LDH baseline levels were associated with a
CR to pembrolizumab [5]. Additionally, elevated LDH baseline levels were reduced at the first scan in
melanoma patients receiving nivolumab or pembrolizumab, who had a better objective rate response
when compared to patients with progressive disease (PD) [15]. To summarize, baseline LDH is a strong
prognostic blood biomarker for stage IV melanoma patients, but has limitations. However, serum LDH
assessment does not have informative utility for assessing stage III melanoma patients receiving CII.
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Blood biomarkers are necessary for real-time monitoring of metastatic melanoma patients during
treatment to allow for more effective decision making on treatment strategies. In the past several
years, our group and others have shown that circulating cell-free nucleic acids (cfNA) have utility
in monitoring metastatic melanoma patients undergoing treatment, particularly using circulating
cell-free DNA (cfDNA) and circulating tumor cells (CTCs) [16–23]. The limitations of studying cfDNA
in melanoma blood samples are the poor extraction efficacy from plasma, large volume of plasma
required for assays, and the limited frequency of genomic aberrations in specific genes that are
detectable [24,25]. The limitations in monitoring CTCs are the robustness of the isolation method used
and the heterogeneity of the CTCs that can limit the interpretation of the findings. To find robust blood
molecular biomarkers, our group has also focused on finding microRNAs (miRs) in melanoma patients’
blood [26] and tumor tissues [27,28]. MiRs are short sequence nucleic acids of 18–22 base pairs length
that have a longer half-life and degrade minimally compared to cfDNA [29,30]. MiRs play significant
roles in controlling and regulating mRNA expression, and thus lead to the activation/deactivation of
specific molecular pathways [29,30]. In most of cancers, including melanoma, miRs are aberrantly
expressed which affects molecular pathways controlling different cellular processes. These miRs can
also be referred to as oncomiRs as they promote tumor development and progression. In melanoma
several miRs have been proposed as tumor biomarkers to determine disease progression [29,31].
Also, significant efforts have been made in determining circulating cell-free miRs (cfmiRs) and
exosomal miRs [29,31]. Recently, by using HTG EdgeSeq miR WTA, we found cfmiR signatures in
plasma samples from patients with melanoma brain metastasis (MBM) [32]. Furthermore, we unraveled
common cfmiR signatures in pre-operative plasma samples taken from stage III and IV melanoma
patients receiving CIIs [32]. The advantage of using HTG EdgeSeq miR WTA to study cfmiRs is that we
can directly profile and quantify >2000 miRs found in plasma samples by next-generation sequencing
(NGS) to identify signature patterns [32]. Moreover, compared to other cfNA assays, the assay requires
a minimal amount of plasma and no tedious extraction procedures.
Our hypothesis is that specific cfmiR signatures found in metastatic melanoma patients’ plasma
samples allows us to perform multiple assessments and provides the clinician with the opportunity
to monitor CII response in real-time. This is important in metastatic melanoma patients’ treatment
management, as resistance to CII followed by rapid disease progression requires immediate decisions
in order to prolong survival. In this study, we compared cfmiR expression to the standard blood
protein biomarker LDH in stage IV melanoma patients. To carry this out, we screened for specific
cfmiRs that were indicative of metastatic melanoma disease in pre- and post-treatment plasma samples
from stage IV melanoma patients compared to normal donors’ plasma samples. By using machine
learning we identified cfmiR signatures that were associated with CII response in stage IV responder
and non-responder patients. Then, we compared the utility of these cfmiRs in predicting CII response
in comparison to LDH levels at baseline and throughout the patients’ follow-ups. CfmiRs produced
consistent results in predicting CII responses compared to elevated LDH levels at baseline and in
longitudinal clinical assessment in stage IV melanoma patients. Finally, we identified cfmiRs that have
potential in determining CII responses in both stage III and IV melanoma patients.
2. Results
2.1. LDH Levels at Treatment Baseline as a Predictive Factor for CII Response in Metastatic Melanoma Patients
In order to identify cfmiRs associated with metastatic melanoma, we assessed plasma from a
cohort of 47 melanoma patients (AJCC 8th edition stage III (n = 24) and IV (n = 23)) seen at the
JWCI/SJHC clinic (Table 1). For each patient a range of 3–6 blood samples were collected and the
samples were categorized as pre- or post-treatment according to the CII start date. Only plasma
samples were included in the study and from this point on all the samples will be referred to as plasma.
The samples were all analyzed using the HTG EdgeSeq miR WTA [32]. All of the patients analyzed had
a median follow-up of 9.7 months and received CII (ipilimumab, nivolumab, pembrolizumab, or the
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combination of ipilimumab and nivolumab) as first line treatment. The 47 patients were divided into
four different cohorts based on stage (III and IV) and CII response (responders and non-responders),
which were analyzed by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 (Figure 1A–D).
The four groups were as follows: stage III responder (group A); stage III non-responder (group B);
stage IV responder (group C); and stage IV non-responder (group D). All of the patients had an
LDH assessment taken at baseline and on longitudinal LDH assessments (average of 11 samples
per patient) during CII (Figure 1A–D). LDH was considered elevated if patients had values taken
>1 the upper limit normal (ULN) [23] (Table 1). Since LDH values at baseline were shown to be
predictive of CII response in previous clinical studies [12–15], we initially compared the LDH levels
at baseline for stage III and IV responder and non-responder patients. Although the sample size
for this analysis is limited, the results showed a significantly higher expression of LDH levels at
baseline in the stage IV non-responder group D when compared to the stage IV responder patients
group C (Figure 1F). As expected, no differences were observed in responder and non-responder
stage III patients (Figure 1E). Similar results were observed when the LDH values were assessed at
3 months after CII in both groups C and D (Figure 1G,H). These results are in agreement with previous
observations showing that the LDH baseline levels predicts response in stage IV patients undergoing
CII [15]. However, when assessing individual patients, the LDH levels were not of prognostic utility,
since only ~54% of stage IV patients (7 of 13 patients) showed a correlation between high LDH levels
and positive CII response. Importantly, the LDH values did not offer any advantage for stage III
melanoma patients in relation to their response to CII.
Table 1. Clinical pathological information for metastatic melanoma patients receiving CII 1 analyzed
for cfmiRs 2 in plasma samples.
Melanoma Patients (n = 47)
Variables n (%)
Age at diagnosis, mean (SD 4) 62.0 (13.9)









AJCC 8th ed. Stages 3
III b/c 24 (51.1)











LDH 6 level at baseline
≤1X 7 ULN 35 (74.5)
>1X ULN 12 (23.5)
1 CII = checkpoint immune inhibitor. 2 Cell-free microRNAs = cfmiRs. 3 AJCC 8th stage = American Joint Committee
on Cancer 8th edition determined at the start date of CII. 4 SD = standard deviation. 5 RECIST = Respond Evaluation
Criteria In Solid Tumors. 6 LDH = lactate dehydrogenase. 7 ULN = upper limit normal.
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Figure 1. Melanoma patients and LDH assessment. (A,B) Swimmer plots showing disease status 
(NED, no evidence of disease; AWD, alive with disease; EXP, expired), RECIST 1.1 criteria (CR, 
complete response; PR, partial response; SD, stable disease; PD, progressive disease), surgery, and 
LDH levels (WNL, within normal; ABN, above normal) in stage III responder (Group A) (A) and non-
responder (Group B) (B) melanoma patients. (C,D) Swimmer plots showing (NED, no evidence of 
disease; AWD, alive with disease; EXP, expired), RECIST 1.1 criteria (CR, complete response; PR, 
partial response; SD, stable disease; PD, progressive disease), surgery, and LDH levels (WNL, within 
normal; ABN, above normal) in stage IV responder (Group C) (C) and non-responder (Group D) (D) 
melanoma patients. (E) Boxplot showing the LDH values (ULN, upper limit normal) at baseline in 
stage III responder and non-responder melanoma patients (NS, non-significant). (F) Boxplot showing 
the LDH values (ULN) at baseline in stage IV responder and non-responder melanoma patients (* p < 
0.05). (G) Boxplot showing the LDH values (ULN) at three months follow-up in stage III responder 
and non-responder melanoma patients (NS, non-significant). (H) Boxplot showing the LDH values 
(ULN) at three months follow-up in stage IV responder and non-responder melanoma patients (** p 
< 0.01). Dots represent outliers in each condition. 
  
Figure 1. Melano pati t t. (A,B) Swimmer plots showing disease status
(NED, no evidence of dise s ; , li it isease; EXP, expired), RECIST .1 criteria (CR,
complete res se; , partial response; SD, stable disease; PD, progressive disease), surgery,
and LDH levels (WNL, within normal; ABN, above normal) in stage III responder (Group A) (A) and
non-responder (Group B) (B) melanoma patients. (C,D) Swimmer plots showing (NED, no evidence
of disease; AWD, alive with disease; EXP, expired), RECIST 1.1 criteria (CR, complete response;
PR, partial response; SD, stable disease; PD, progressive disease), surgery, and LDH levels (WNL,
within normal; ABN, above normal) in stage IV responder (Group C) (C) and non-responder (Group D)
(D) melanoma patients. (E) Boxplot showing the LDH values (ULN, upper limit normal) at baseline in
stage III responder and non-responder melanoma patients (NS, non-significant). (F) Boxplot showing
the LDH values (ULN) at baseline in stage IV responder and non-responder melanoma patients
(* p < 0.05). (G) Boxplot showing the LDH values (ULN) at three months follow-up in stage III
responder and non-responder melanoma patients (NS, non-significant). (H) Boxplot showing the LDH
values (ULN) at three months follow-up in stage IV responder and non-responder melanoma patients
(** p < 0.01). Dots represent outliers in each condition.
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2.2. Identification of cfmiRs in Pre- and Post-Treatment Samples from Patients Non-Responsive to CII
In evaluating the utility of cfmiRs, it is important to find cfmiRs that have applicability in real-time
monitoring of melanoma patient’s disease status before and during CII(s) to evaluate response.
Recently, we have shown that specific cfmiR patterns found in MBM patients’ plasma may have utility
in monitoring melanoma patients undergoing treatment [32]. Our hypothesis is that specific cfmiRs
have a better utility compared to serum LDH levels in the assessment of melanoma patients undergoing
CII. To address this hypothesis, pre-treatment samples (n = 13) from 13 stage IV melanoma patients who
progressed (group D) were compared to normal donors’ samples (n = 73). A total of 162 differentially
expressed (DE) cfmiRs were observed in the melanoma samples, of which 89 were upregulated and
73 were downregulated. To determine which cfmiRs classify metastatic melanoma patients from
normal donors’ samples, we implemented a Random Forest algorithm to the 162 DE cfmiRs identified.
The analysis generated a cfmiR classifier signature consisting of 12 cfmiRs (Figure 2A, Figure S1,
and Table 2). To identify DE cfmiRs associated with disease progression during CII, 26 post-treatment
samples collected from 13 stage IV non-responder (group D) melanoma patients were compared
to normal donors’ samples. In each analysis 215 and 202 DE cfmiRs were found. Random Forest
algorithm was applied to the 215 and 202 DE cfmiRs identified (Figure 2A, Figures S2 and S3).
The top and commonly identified nine cfmiRs were selected as potential cfmiR biomarkers to monitor
disease progression on melanoma patients undergoing CII (Table 2 and Figure 2B). Then, the levels
of those nine cfmiRs were compared in pre-treatment, post-treatment, and normal donors’ samples.
Of the nine cfmiRs identified, eight (miR-1234-3p, miR-3175, miR-4271, miR-4649-3p, miR-4745-3p,
miR-615-3p, miR-6511-3p, and miR-6794-5p) were further evaluated since they showed significant
changes in pre- and post-treatment samples from stage IV non-responders (Figure S4A–I). To summarize,
using 13 paired blood samples (13 pre- and 26 post-treatment samples) nine cfmiRs were found as a
potential biomarker for stage IV non-responder (group D) melanoma patients. Only eight of the nine
cfmiRs were significantly DE in melanoma patients’ compared to normal donors’ samples.
2.3. MiR-615-3p Correlates with Melanoma Response to CII
To determine whether the cfmiRs identified in stage IV non-responder patients had clinical
utility to monitor patients’ treatment, we selected nine pre- and post-treatment samples from stage
IV patients (group C) that responded to CII-treatment (achieved objective rate response, PR or CR).
Of those nine patients, four reached CR (Figure 3A) and five patients had a partial response (PR)
(Figure 3B). All of the samples were analyzed to determine the levels of the eight cfmiRs in the pre-
and post-treatment samples. MiR-4649-3p, miR-1234-3p, and miR-615-3p levels significantly decreased
in the post-treatment samples of the stage IV responder patients who had a CR (Figure 3C–E), but the
levels did not change significantly for miR-3175, miR-4271, miR-4745-3p, miR-6511-3p, and miR-6794-5p
(Figure S5A–E). On the contrary, in patients who had a PR no significant differences were observed in
pre- and post-treatment samples for any of the eight cfmiRs assessed (Figure 3F–H and Figure S5F–J).
To validate our observation, we assessed the expression levels of miR-615-3p in plasma samples
from two stage IV responder and non-responder patients. Stage IV non-responder patients who
progressed during CII had a significant increase in the expression of miR-615-3p (Figure 3I,J). In both
cases LDH levels were unable to detect melanoma disease progression (Figure 3I,J). On the contrary,
responder patients showed a decrease in miR-615-3p levels in post-treatment samples (Figure 3K,L).
Similarly, LDH levels were also unable to detect CII response (Figure 3K,L). Then, we analyzed the
detection levels of miR-615-3p for its ability to monitor stage III patients. To do that we compared
pre- and post-treatment samples. The post-treatment samples were selected based on the patients’
RECIST 1.1 criteria. All of the patients had PD at some point during treatment, but at the time point of
blood collection, only 8 patients had PD. MiR-651-3p was significantly increased in melanoma patients
with PD compared to pre-treatment samples (Figure S6A). More importantly, miR-615-3p was able to
monitor stage III non-responder melanoma patients during CII (Figure S6B). Finally, we compared
the expression of miR-615-3p in pre- and post-treatment samples from stage III responders. For the
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12 post-treatment samples selected, the patients achieved CR at the time point of blood collection.
No significant differences were observed for miR-615-3p in stage III responder patients (Figure S6C).
Similar analysis were performed for miR-4649-3p and the results were consistent with those observed
for miR-615-3p (Figure S7A–E). To summarize, the cfmiR signature was successful in identifying
stage IV responders during CII-treatment. MiR-4649-3p, miR-1234-3p, and miR-615-3p levels were
associated with a CR in stage IV patients undergoing CIIs and were useful in monitoring responses of
stage IV melanoma patients undergoing CII. Also, the results demonstrated differences for miR-615-3p
in detecting stage III patients with PD, but failed to identify stage III patients with CR.Cancers 2020, 12, x FOR PEER REVIEW 7 of 19 
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Table 2. CfmiR 1 classifiers commonly identified by Random Forest in stage IV patients that had PD 2.
Probe Pre-Treatment FIS 3 Post-Treatment-1 FIS 3 Post-Treatment-2 FIS 3
miR-4271 0.06 0.05 0.07
miR-3175 0.05 0.05 0.04
miR-4745-3p 0.04 0.01 0.02
miR-6862-3p 0.03 N/A N/A
miR-4649-3p 0.03 0.04 0.02
miR-6510-3p 0.02 0.01 N/A
miR-4306 0.01 0.02 0.02
miR-1234-3p 0.01 0.05 0.01
miR-6511a-3p 0.01 0.04 0.01
miR-615-3p 0.01 0.02 0.02
miR-6794-5p 0.01 0.02 0.03
miR-1301-5p 0.01 0.02 N/A
1 CfmiR = cell-free miRNA. 2 PD = progressive disease. 3 FIS = Feature Importance Scores.
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Gray solid line indicates the upper limit normal (ULN) for LDH. Black dotted line indicates the average
level of miR-615-3p detected in normal healthy donors’ plasma samples. Green solid line indicates the
start of CII.
2.4. A cfmiR Signature to Assess CII Responses in Stage III Melanoma Patients
To find specific cfmiRs associated with stage III and CII response, 24 stage III patients (22 stage
IIIC and 2 stage IIIB) undergoing CII were examined, of which 12 were responders (group A;
Figure 1A) and 12 were non-responders (group B; Figure 1B). Initially, we compared the cfmiR
expression in pre-treatment samples taken from stage III responders (group A) versus non-responders
(group B). Surprisingly, miR-3197 was the only significantly DE cfmiR in the comparison (Figure 4A,B).
MiR-3197 differentiated stage III responders from non-responders in pre-treatment samples (Figure 4B).
Additionally, miR-3197 showed significant differences when comparing pre-treatment samples from
responders versus normal donors’ samples (Figure 4B). This suggested that the cfmiRs detected in
stage III patients are not significantly changing compared to normal donors’ samples. This is likely
related to low tumor burden and low doubling time of stage III tumors being treated with CII.
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In order to find biomarkers to monitor metastatic melanoma patients and increase our sample size,
we combined stage III/IV melanoma patients and grouped them as non-responders and responders
to CII. Then, non-responder and responder samples were compared to normal donors’ samples,
respectively. A total of 286 DE cfmiRs (158 upregulated and 128 downregulated) were found in CII
pre-treatment samples from the responder group compared to normal samples (Figure 4C). We then
compared the pre-treatment samples from the non-responder patients versus normal donors’ samples.
In the analysis, 253 DE cfmiRs (158 upregulated and 95 downregulated) were observed in non-responder
patients compared to normal donors’ samples (Figure 4C). It is important to find cfmiRs that are
useful for the monitoring of CII responses and to help distinguish metastatic melanoma responders
from non-responders. Therefore, we focused on the detection of DE cfmiRs that were observed
associated with non-response or response to CII. Therefore, we calculated the ratio of the FCs obtained
in responders versus normal donors’ samples and in non-responders versus normal donors’ samples.
Only cfmiRs with a ratio FC <0.75 were included. A total of 92 cfmiRs were DE in responders’ compared
to normal donors’ and non-responders’ samples (Table S1).
We proposed that specific cfmiRs have the potential to identify patients who will respond to CII.
By applying the same strategy but considering a ratio FC >1.25, 17 DE cfmiRs were found in stage
III/IV non-responders’ compared to normal donors’ and responders’ samples (Table S2). The cfmiRs
identified may represent potential biomarkers to determine patients who will likely develop PD to CII.
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MiR-1273e, miR-584-5p, and miR-1290 were found increased in non-responders stage III/IV melanoma
patients. Surprisingly, the same cfmiRs were also found elevated in pre-operative MBM plasma
samples as previously described by our group [32]. To summarize, 92 cfmiRs found in pre-treatment
samples distinguished stage III/IV responders’ from non-responders’ and normal donors’ samples.
On the contrary, 17 cfmiRs differentiated stage III/IV non-responders from responders and normal
donors’ samples.
3. Discussion
Notwithstanding the large number of clinical and translational research studies, there is still a dire
need for more reliable and informative blood biomarkers to better evaluate CII responses in real-time in
melanoma patients. Metastatic melanoma progression can be rapid once tumors develop resistance to
CIIs and bypass the host systemic immune control. Better blood biomarkers that can identify real-time
changes in the patient’s disease status and allow for active monitoring could translate into earlier
treatment decision making. There is evidence showing that higher baseline LDH values are associated
with CII responses [13–15,33] and can allow for monitoring CII [15], but often the levels of LDH do not
correlate with disease progression in patients receiving CII. Thus, it is difficult to rely on longitudinal
LDH level assessment to make early clinical decisions in patients who are undergoing unsuccessful CII.
Our study provides a detailed profiling of cfmiRs that potentially allow for the monitoring of stage III
and IV melanoma patients during CII.
Despite the significant advances in improving progression-free survival (PFS) and OS, a high
percentage of patients will still develop resistance and experience recurrence within the first year of
starting CII [34]. Several studies have been conducted to identify miR biomarkers in melanoma tissues
and/or plasma/serum that could predict melanoma progression [35,36]. However, most of the proposed
cfmiRs are not validated or they represent single cfmiRs with limited reproducibility, and non-specific
overlapping with benign diseases or normal healthy donor levels. In identifying biomarkers for CII
response, some groups have focused on specific deregulated miRs in the tumor that can modulate the
immune response against melanoma tumors, and thus control CII response. For example, miR-30b is
upregulated in melanoma patients’ tissues and correlates to different clinical variables such as stage,
metastatic potential, and shorter OS. MiR-30b promotes immunosuppression by targeting GALNT7
(N-Acetylgalactosaminyltransferase 7) and increasing IL-10 production [37]. We observed an increased
level of circulating cfmiR-30b in both responder and non-responder melanoma stage III/IV patients
compared to normal donors’ samples. Also, an increase in cfmiR-30b levels was observed in responder
compared to non-responder patients. In another study, miR-210 was shown to be upregulated in
hypoxic areas of the tumor controlling cytotoxic T lymphocytes meditated lysis [38]. To summarize,
miR-210 mediates its effects by targeting PTPN1, HOXA1, and TP53I11 [38]. These studies support the
role of elevated miRs in promoting melanoma progression in response to CII. However, the translational
value of these findings into clinical biomarkers would require an assessment of the miRs in longitudinal
biopsies of the tumor, which is not always feasible.
Blood biomarkers represent the most logistical and promising way to actively monitor patients in
real-time during CII. Other studies have shown an eight cfmiR signature (miR-146a, miR-155, miR-125b,
miR-100, let-7e, miR-125a, miR-146b, and miR-99b) found in extracellular vesicles released by metastatic
melanoma tumors which were found to be associated with an increase in myeloid-derived suppressor
cells and resistance to ipilimumab and nivolumab therapy [39]; however, not all of the cfmiRs identified
were DE in melanoma patients when compared to normal donors’ samples. Our findings revealed
that cfmiRs (miR-1234-3p, miR-3175, miR-4271, miR-4649-3p, miR-4745-3p, miR-615-3p, miR-6511-3p,
and miR-6794-5p) are detected in pre-treatment plasma samples. Only miR-1234-3p, miR-4649-3p
and miR-615-3p were significantly enhanced in post-treatment samples from stage IV non-responder
patients. Accordantly, miR-4649-3p, miR-1234-3p, and miR-615-3p decreased in post-treatment samples
of stage IV responder patients who had a CR during CII. Whereas, no significant differences were
observed in stage IV responder patients who had a PR in comparison to pre-treatment samples.
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On longitudinal blood assessment, miR-615-3p and miR-4649-3p showed promising clinical utility in
monitoring CII response in stage IV responder and non-responder patients. MiR-615-3p was previously
detected and listed as a potential cfmiR for metastatic melanoma [40], but its function in melanoma
is unknown [41]. To our knowledge, there is not report of the miR-4649-3p function in melanoma;
however, it was previously reported that miR-4649-3p inhibits cell proliferation by targeting protein
tyrosine phosphatase SHP-1 in nasopharyngeal carcinoma cells [42].
Identifying informative cfmiR biomarkers for stage IIIB-D melanoma is challenging, as the
tumor size is variable ranging from multinodal micrometastasis to macrometastasis, with often
variable growth rates. In this study, plasma samples derived from 24 melanoma patients undergoing
CII (22 stage IIIC and 2 stage IIIB) were examined. As shown in previous studies [13–15,33] and
in the present study, LDH baseline level assessment was successful in identifying most of stage
IV patients, but it was not a reliable prognostic factor for stage III patients. When comparing
stage III responders versus non-responders, only miR-3197 was found DE. Factors influencing the
detection of cfmiRs changing could be associated with individual cfmiR variability, tumor burden,
and tumor heterogeneity. To address this problem and to identify cfmiRs able to monitor metastatic
melanoma, stage III and IV melanoma responders and non-responders were compared to normal
donor samples. We found 92 cfmiRs associated with CII response. Whether any of these cfmiRs can be
used as a robust biomarker will require further investigation. Also, 17 cfmiRs have shown potential
applicability to determine stage III/IV melanoma patients who will not respond to CII. Relevant to this,
we observed that miR-1273e, miR-584-5p, and miR-1290 have also been detected in MBM patients’
plasma. These cfmiRs may be indicators of III/IV melanoma patients who will eventually develop
MBM. Recently, Walbrecq et al. identified miR-1290 as a novel hypoxia-associated miR, which is highly
abundant in hypoxic extracellular vesicles released by melanoma cells [43].
Similar to CII resistance, different mechanisms have been associated with BRAF and MEK inhibitors
resistance in metastatic melanoma. Often, these mechanisms over-activate the mitogen-activated
protein kinase (MAPK) pathway and overcome BRAF and MEK inhibitors effects [44–46]. It has been
proposed that similar mechanisms may drive CII resistance, as MAPK pathway can be over-active
in CII-treated melanoma tumors [45]. Thus, it is also important to determine whether elevated
miRs regulate MAPK pathway. In a previous study, high levels of miR-125b-5p were shown to be
associated with Vemurafenib (BRAF inhibitor) resistance [47,48]. Accordingly, we observed that
miR-125b was elevated in CII non-responder patients, but decreased in responding patients to CII
(Table S1). Thus, miR-125b-5p may represent an example of overlapping roles for miRs in promoting
cross-resistance to both BRAF and MEK inhibitors and CII.
We understand the limitations of our study in analyzing melanoma patients receiving different
types of CII. Therefore, these findings may represent cfmiRs associated with responses to different
CII. Future analyses are required to confirm and validate whether the cfmiRs have the ability to
determine treatment response in well-defined cohort of patients receiving specific CII. To the best of
our knowledge, this is the first report showing the potential ability of cfmiRs to distinguish patients
who are non-responsive to CII from normal donors’ plasma samples. Further studies are needed to
validate our observations in prospective clinical trials on larger sample sizes of metastatic melanoma
patients undergoing CII(s).
4. Materials and Methods
4.1. Consent to Participate and Patient Specimen Accrual
This single-center study followed the principles found in the Declaration of Helsinki. All human
samples and clinical information for this study were obtained according to the protocol guidelines
approved by Saint John’s Health Center (SJHC)/John Wayne Cancer Institute (JWCI) Joint Institutional
Review Board (IRB): JWCI Universal Consent (Providence Health and Services Portland IRB:
JWCI-18-0401) and Western IRB: MORD-RTPCR-0995. Informed consent was obtained from all
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participants. The study was a prospective study designed to assess cfNA in CII-treated patients seen
at JWCI/SJHC. All specimens were de-identified and entered into a restricted access database by a
database operator.
4.2. Blood Sample Collection
Blood samples of healthy donors and melanoma patients were prospectively collected at
SJHC/JWCI. Briefly, all blood samples were collected from 2016–2020 in Streck blood collection
tubes (Streck, La Vista, NE, USA). Blood samples were accrued and processed to obtain plasma.
Plasma was centrifuged, filtered, aliquoted, barcoded, and cryopreserved at −80◦C as previously
described [16]. Aliquots of plasma were thawed only once, mixed, and centrifuged before being
analyzed by HTG EdgeSeq miR WTA.
For HTG EdgeSeq miR WTA analysis plasma samples (n = 73) were collected from normal
healthy donors ranging in age from 21–65 years old, of which 41 were females and 32 were males.
Pre-treatment samples (n = 47) were collected from AJCC 8th stage III and IV melanoma patients
who received CII (Table 1). From the same CII- treated patients 2–5 blood samples (n = 111) that
were collected post-treatment (after the first dose and during CII). All plasma samples were analyzed
by HTG EdgeSeq miR WTA analysis. Overall, 158 melanoma plasma samples were analyzed from
47 patients. The melanoma patients analyzed had detailed clinical follow-up information and treatment
response assessments as described in Section 4.3 below. The clinical demographics information for the
47 melanoma patients analyzed is summarized in Table 1.
4.3. CII Response
Every patient had a follow-up evaluation at the JWCI/SJHC cancer clinic as recommended in
the current standard of care. The median follow-up was 9.7 months for the 47 patients analyzed.
Each patient included in the study received at least four doses of the approved CII drugs (ipilimumab,
nivolumab, pembrolizumab, or the combination of ipilimumab and nivolumab [16]) and were assessed
for the RECIST 1.1. Briefly, CII responses were assessed using computerized tomography/magnetic
resonance imaging every three months according to RECIST 1.1 criteria, denoting PD, SD (stable disease),
PR, and CR. Based on RECIST 1.1 criteria the patients were stratified into responders (PR/CR) and
non-responders (PD). Stage III patients who received surgery before receiving CII were considered
NED until evaluated for RECIST 1.1. Stage III patients (3A, 4A, 7A, 8A, 9A, 10A, and 12A) from group
A and patients (3B, 5B, 6B, 7B, 8B, 9B, 10B, and 11B) from group B received surgery and adjuvant
treatment. This prospective study was performed in accordance with the REMARK guidelines [49,50].
LDH levels were evaluated using Dimension Vista LDH (LDI) Flex reagent cartridge (cat# K2054)
an in vitro diagnostic test for the quantitative measurement of LDH in human serum on the Dimension
Vista System analyzer (Siemens Medical Solutions Inc., PA, USA) at the SJHC Clinical Chemistry
Department. LDH baseline and subsequent values were obtained for each patient. At least 3 LDH
values were collected at different time points for all of the patients. Elevated LDH levels were
considered in patients with >1X ULN (>240 U/L).
4.4. Sample Processing for HTG WTA
Melanoma patients’ and normal donors’ plasma samples were computer coded and de-identified
during processing and assessing. The melanoma patients’ and normal donors’ plasma samples
processing and NGS library preparation, quality control, normalized, and pooled was performed as
described previously [32]. The pool library was sequenced on MiSeq or NextSeq 550 instruments
following the respective Illumina instrument sequencing protocols. FASTQ files were generated from
raw sequencing data using Illumina BaseSpace BCL to FASTQ software version 2.2.0 and Illumina Local
Run Manager Software version 2.0.0. FASTQ files were analyzed with HTG EdgeSeq Parser software
version v5.1.724.4793 to generate raw counts for 2083 miRs per sample. An .xls file containing the final
counts for 2083 miRs per sample was generated for downstream data analysis. Data normalization
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was performed as discussed in Biostatistical analysis. Each HTG EdgeSeq miR WTA included negative
(CTRL_ANT1, CTRL_ANT2, CTRL_ANT3, CTRL_ANT4, CTRL_ANT5) and positive (CTRL_miR_POS)
miR controls. In all runs, Human Brain Total RNA (Ambion, Inc., Austin, TX, USA) was used as a
control for library preparation, but they were not sequenced. All the samples that did not pass the
quality control set by the HTG REVEAL software version 2.0.1 (Tuscon, AR, USA) were excluded from
the analysis.
4.5. Biostatistical Analysis
The DESeq2 data normalization, analyses, and statistical comparisons for the melanoma (pre- and
post-treatment) and normal donors’ plasma samples were all performed using the HTG REVEAL
software version 2.0.1. In all of the comparison only cfmiRs with a log2 fold-change (Log2FC) >1.2 or
<−1.2, a false discovery rate (FDR) > 0.05, and normalized counts greater than 30 were only considered.
Ratio of the FCs was calculated by dividing the FC in non-responder versus normal to the FC of
responder versus normal. Data normal distribution was evaluated by Shapiro-Wilk normality test.
According to data normal distribution Kruskal-Wallis (non-normal distribution) tests were performed
to determine differences among three or more groups. Mann-Whitney U-test (non-normal distribution)
analysis was performed to compare differences between two groups. Box plots were performed
with GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). To visualize the sequence
and duration of treatments, patient response, and LDH levels, swimmer plots were employed using
ggplot2 package version 3.3.2.9000 [51,52]. The swimmer plots were carried out using R version 4.0.0
(R Core Team) [52]. Data processing and Random Forest algorithm were performed using Python
3.7.7 using Scikit-learn and other packages as previously described in [32]. A two-sided p-value < 0.05
was considered statistically significant: * p < 0.05; ** p < 0.01; *** p < 0.001, and a p-value > 0.05
was considered non-significant (NS). The figures were processed using CorelDraw graphics suite 8X
(Corel Corporation, Ottawa, Canada).
4.6. Data Deposit
The data generated and discussed in this study has been deposited in the NCBI’s Gene Expression
Omnibus (GEO) and is accessible through the GEO Series accession number GSE157370.
5. Conclusions
In this prospective study, specific cfmiR signatures were found in plasma samples from metastatic
melanoma patients. Three cfmiRs that were elevated in pre- and post-treatment plasma samples of stage
IV non-responder patients were found to be downregulated in post-treatment plasma samples from
patients who responded to CII and vice versa (see the Graphical Abstract). In addition, we proposed
cfmiRs that may have the potential prognostic value to assess stage III/IV melanoma patients who
will progress during CII. The present pilot study revealed specific cfmiRs that can help in monitoring
CII response. MiR-615-3p and miR-4649-3p demonstrated a higher efficiency than LDH at baseline or
during CII to monitor stage IV patients undergoing CII.
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patients, Table S1: CfmiR identified in pre-treatment samples of stage III/IV responders, Table S2: CfmiR identified
in pre-treatment samples of stage III/IV non-responders.
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